Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 3;7(5):pkad062.
doi: 10.1093/jncics/pkad062.

In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer

Dawson Hill  1 , Samuel R Kaufman  1 , Mary K Oerline  1 , Kassem Faraj  1 , Megan E V Caram  2   3 , Vahakn B Shahinian  1   4 , Brent K Hollenbeck  1 , Avinash Maganty  1
Affiliations

In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer

Dawson Hill et al. JNCI Cancer Spectr. .

Abstract

Background: Management of men with advanced prostate cancer has evolved to include urologists, made possible by oral targeted agents (eg, abiraterone or enzalutamide) that can be dispensed directly to patients in the office. We sought to investigate whether this increasingly common model improves access to these agents, especially for Black men who are historically undertreated.

Methods: We used 20% national Medicare data to perform a retrospective cohort study of men with advanced prostate cancer from 2011 through 2019, managed by urology practices with and without in-office dispensing. Using a difference-in-difference framework, generalized estimating equations were used to measure the effect of in-office dispensing on prescriptions for abiraterone and/or enzalutamide, adjusting for differences between patients, including race.

Results: New prescription fills for oral targeted agents increased after the adoption of in-office dispensing (+4.4%, 95% confidence interval [CI] = 3.4% to 5.4%) relative to that for men managed by practices without dispensing (+2.4%, 95% CI = 1.4% to 3.4%). The increase in the postintervention period (difference-in-difference estimate) was 2% higher (95% CI = 0.6% to 3.4%) for men managed by practices adopting dispensing relative to men managed by practices without dispensing. The effect was strongest for practices adopting dispensing in 2015 (difference-in-difference estimate: +4.2%, 95% CI = 2.3% to 6.2%). The effect of dispensing adoption did not differ by race.

Conclusion: Adoption of in-office dispensing by urology practices increased prescription fills for oral targeted agents in men with advanced prostate cancer. This model of delivery may improve access to this important class of medications.

PubMed Disclaimer

Conflict of interest statement

All authors have no conflicts of interests or disclosures.

Figures

Figure 1.
Figure 1.
Adjusted probability of receiving a new prescription for abiraterone and/or enzalutamide before and after adoption of in-office dispensing.
Figure 2.
Figure 2.
Adjusted probability of receiving a new prescription for abiraterone and/or enzalutamide before and after adoption of in-office dispensing, stratified by year of adoption: (A) 2015, (B) 2016, and (C) 2017.
Figure 3.
Figure 3.
Adjusted probability of receiving a new prescription for abiraterone and/or enzalutamide before and after adoption of in-office dispensing, stratified by race: (A) non-Black men and (B) Black men.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Fizazi K, Tran N, Fein L, et al.; for the LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-360. doi:10.1056/NEJMoa1704174. - DOI - PubMed
    1. Caram MEV, Borza T, Min HS, et al.Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare part D. J Oncol Pract. 2017;13(8):e694-e702. doi:10.1200/JOP.2016.020206. - DOI - PMC - PubMed
    1. Caram MEV, Oerline MK, Dusetzina S, et al.Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer. 2020;126(23):5050-5059. doi:10.1002/cncr.33176. - DOI - PMC - PubMed
    1. Kanter GP, Parikh RB, Fisch MJ, et al.Trends in medically integrated dispensing among oncology practices. J Clin Oncol Oncol Pract. 2022;18(10):e1672-e1682. doi:10.1200/OP.22.00136 - DOI - PMC - PubMed
    1. Caram MEV, Kaufman SR, Modi PK, et al.Adoption of abiraterone and enzalutamide by urologists. Urology. 2019;131:176-183. doi:10.1016/j.urology.2019.05.012. - DOI - PMC - PubMed

Publication types

LinkOut - more resources